Loading…
6 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Vitamini 2017 | Pharma | 2.8% | 18th pct | 110 |
| Evrazia Export | FMCG | — | no FY data | 543 |
| Denola | Industrial Goods | — | no FY data | 534 |
| Dijital Eds | (unclassified) | — | no FY data | 1208 |
| Realtrans Solutions | (unclassified) | — | no FY data | 1208 |
| Mega Mall | (unclassified) | — | no FY data | 1208 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
Only 1 of 6 peers filed FY2024. Switch to FY2018 (6 of 6).
| Ratio — FY 2024 | Vitamini 2017 | Evrazia Export | Denola | Dijital Eds | Realtrans Solutions | Mega Mall |
|---|---|---|---|---|---|---|
| Margins | ||||||
| Gross Margin | 9.1% | — | — | — | — | — |
| EBITDA Margin | 2.8% | — | — | — | — | — |
| EBITDAR | 3,341 | — | — | — | — | — |
| EBITDAR Margin | 2.8% | — | — | — | — | — |
| EBIT Margin | 2.7% | — | — | — | — | — |
| Net Profit Margin | 2.7% | — | — | — | — | — |
| Operating Expense % of Sales | 6.3% | — | — | — | — | — |
| Returns | ||||||
| Return on Assets (ROA) | 19.5% | — | — | — | — | — |
| Return on Equity (ROE) | 20.9% | — | — | — | — | — |
| ROIC [EBIT / Invested Capital] | 23.0% | — | — | — | — | — |
| Leverage & debt balances | ||||||
| Debt-to-Assets | 0.0% | — | — | — | — | — |
| Debt-to-Equity | 0.00x | — | — | — | — | — |
| Debt-to-EBITDA | 0.00x | — | — | — | — | — |
| Equity-to-Assets | 93.1% | — | — | — | — | — |
| Net Debt | -1,571 | — | — | — | — | — |
| Cash & Equivalents | 1,571 | — | — | — | — | — |
| Total Debt | N/A | — | — | — | — | — |
| Liquidity & working capital | ||||||
| Current Ratio | 13.52x | — | — | — | — | — |
| Quick Ratio | 10.71x | — | — | — | — | — |
| Cash Ratio | 1.36x | — | — | — | — | — |
| Total Current Assets | 15,570 | — | — | — | — | — |
| Total Current Liabilities | 1,152 | — | — | — | — | — |
| Inventory | 3,236 | — | — | — | — | — |
| Trade Receivables | 10,626 | — | — | — | — | — |
| Trade Payables | 1,152 | — | — | — | — | — |
| Net Working Capital | 14,418 | — | — | — | — | — |
| Net Working Capital % of Revenue | 12.1% | — | — | — | — | — |
| Trade Working Capital | 12,710 | — | — | — | — | — |
| Trade Working Capital % of Revenue | 10.6% | — | — | — | — | — |
| Change in Trade Working Capital | N/A | — | — | — | — | — |
| Turnover & efficiency | ||||||
| Inventory Turnover | 33.59x | — | — | — | — | — |
| Days Inventory Outstanding (DIO) | 10.9 | — | — | — | — | — |
| Receivables Turnover | 11.25x | — | — | — | — | — |
| Days Sales Outstanding (DSO) | 32.4 | — | — | — | — | — |
| Payables Turnover | 94.33x | — | — | — | — | — |
| Days Payable Outstanding (DPO) | 3.9 | — | — | — | — | — |
| Cash Conversion Cycle | 39.4 days | — | — | — | — | — |
| Asset Turnover | 7.14x | — | — | — | — | — |
| Cash flow & dividends | ||||||
| Operating Cash Flow | 658 | — | — | — | — | — |
| Free Cash Flow (OCF − Capex proxy) | 133 | — | — | — | — | — |
| Cash Conversion (OCF / EBITDA) | 19.7% | — | — | — | — | — |
| Dividends Declared | 800 | — | — | — | — | — |
| Dividend Payout Ratio | 24.5% | — | — | — | — | — |